The Hedge Fund Senzar Asset Management Llc Upped its Position in Exact Sciences Corp (Put) (NASDAQ:EXAS) by $21.45 Million

May 17, 2018 - By Elizabeth Jones

Exact Sciences Corporation (NASDAQ:EXAS) Corporate LogoBig Money Sentiment decreased to 0.88 in 2017 Q4. It has change of 0.13, from 2017Q3’s 1.01. The ratio is negative due to EXAS positioning: 25 sold and 105 reduced. 44 funds took holdings and 70 increased holdings. Investors holded 93.65 million in 2017Q3 but now own 92.48 million shares or 1.24% less. Moreover, Zeke Cap Limited Com has 0.03% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 5,668 shs. Putnam Investments Ltd Liability invested in 0% or 38,121 shs. Moors & Cabot holds 4,501 shs or 0.03% of its capital. Elk Creek Prtn Ltd Limited Liability Company has invested 1.79% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Swiss State Bank invested in 0.01% or 202,819 shs. 14,017 were accumulated by Aperio Group Incorporated Ltd Liability. Brown Advisory Inc invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Mutual Of America Cap Mgmt Ltd owns 0.08% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 105,954 shs. Salem Inv Counselors holds 6,480 shs or 0.04% of its capital. Parallax Volatility Advisers Limited Partnership invested in 0% or 17,892 shs. Creative Planning holds 53,306 shs. Pnc Gp has 42,048 shs. Lincoln National holds 0.03% of its capital in Exact Sciences Corporation (NASDAQ:EXAS) for 20,736 shs. Canada Pension Plan Board owns 942,700 shs. Nuveen Asset Limited Company invested in 0.01% or 23,844 shs.

EXAS had 21 selling transactions and 0 insider purchases since January 2, 2018. This’s net activity of $25.11 million. COWARD D SCOTT had sold 4,420 shs worth $187,134. Elliott Jeffrey Thomas also sold $126,252 worth of Exact Sciences Corporation (NASDAQ:EXAS) shs. $6.62 million worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Conroy Kevin T. Shares for $126,925 were sold by Doyle James Edward. Zanotti Katherine S had sold 7,232 shs worth $325,440. Shares for $381,447 were sold by WYZGA MICHAEL S on Thursday, May 10.

According to 2018Q1 SEC regulatory filling Senzar Asset Management Llc upped its holdings in Exact Sciences Corp (Put) (NASDAQ:EXAS) by 9679.82%. Exact Sciences Corp (Put) (NASDAQ:EXAS) declined 19.82% with the market as Senzar Asset Management Llc bought 536,359 shares. Senzar Asset Management Llc announced $21.86 million position in Senzar Asset Management Llc for 2018Q1. Now it holds 541,900 shares, compared to 5,541 last quarter. $6.21B is the market cap of Exact Sciences Corp (Put). EXAS is touching $50.96 during the last trading session, after increased 0.37%.Currently Exact Sciences Corporation is uptrending after 81.43% change in last May 17, 2017. EXAS has 1.04 million shares volume. EXAS outperformed the S&P500 by 69.88%.

The Senzar Asset Management Llc’s stake in Aetna Inc New (NYSE:AET) was decreased by 96,300 shares to 43,900 shares valued at $7.42M in 2018Q1, according to the regulatory filling. It operates about $442.00M and $316.94M US longs. Senzar Asset Management Llc cut its stake in Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) and reduced Cvs Health Corp (NYSE:CVS) position by 194,670 shares for a total of 120,830 shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

In total 11 analysts cover Exact Sciences (NASDAQ:EXAS). “Buy” rating has 8, “Sell” are 0, while 3 are “Hold”. (NASDAQ:EXAS) has 73% bullish analysts. 16 are the (NASDAQ:EXAS)’s ratings reports on 17 May 2018 according to StockzIntelligence Inc. On Tuesday, April 3 BTIG Research upgraded Exact Sciences Corporation (NASDAQ:EXAS) to “Buy” rating. The stock rating was maintained by Benchmark with “Buy” on Wednesday, January 17. On Thursday, March 29 William Blair maintained Exact Sciences Corporation (NASDAQ:EXAS) with “Buy” rating. In Friday, February 23 report Canaccord Genuity maintained the stock with “Buy” rating. On Friday, February 23 Benchmark downgraded the shares of EXAS in report to “Hold” rating. On Tuesday, February 27 the firm has “Outperform” rating by Robert W. Baird given. On Tuesday, March 27 the rating was maintained by Jefferies with “Buy”. On Friday, February 23 the firm earned “Hold” rating by Stephens. On Friday, April 27 the firm earned “Buy” rating by Canaccord Genuity. In Monday, March 19 report Canaccord Genuity maintained the stock with “Buy” rating.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The company has $6.21 billion market cap. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Currently it has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: